¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, À¯Çüº°, Åõ¿© °æ·Îº°, ȯÀÚ ¼Ó¼ºº°, Áö¿ªº°
Biopharmaceutical and Biomedicine Market, By Product Type, By Application, By Type, By Route of Administration, By Patient Demographics, By Geography
»óǰÄÚµå : 1672781
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀº 2025³â¿¡´Â 6,402¾ï 6,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 1Á¶ 4,251¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 12.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ 2024 2025³â ½ÃÀå ±Ô¸ð 6,402¾ï 6,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 12.10% 2032³â °¡Ä¡ ¿¹Ãø 1Á¶ 4,251¾ï 7,000¸¸ ´Þ·¯
µµÇ¥. ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀÇ Áö¿ªº° Á¡À¯À²(%), 2025³â
Biopharmaceutical and Biomedicine Market-IMG1

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀº Áö³­ ¼ö½Ê³â°£ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» °ÅµìÇØ ¿Ô½À´Ï´Ù. °ø°ø ¹× ¹Î°£ ºÎ¹®ÀÇ R&D ÅõÀÚ Áõ°¡´Â »ý¹°Á¦Á¦, À¯Àü°øÇÐ, ½Å¾à °³¹ß ºÐ¾ß¿¡¼­ ȹ±âÀûÀÎ ±â¼ú Çõ½ÅÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á, Àç»ýÀÇ·á, ´ÜŬ·Ð Ç×ü, °³ÀθÂÃãÇü ÀÇ·á¿Í °°Àº ºÐ¾ßÀÇ ¹ßÀüÀº ¸¸¼ºÁúȯ°ú »ý¸íÀ» À§ÇùÇÏ´Â Áúº´À» Ä¡·áÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Àü¸ÁÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. Àα¸ÀÇ ±Þ¼ÓÇÑ °í·ÉÈ­¿Í ¾Ï, ´ç´¢º´, ½Å°æÁúȯÀÇ Àü ¼¼°è ¹ßº´·ü Áõ°¡´Â º¸´Ù È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇÕ¼º»ý¹°Çаú À¯Àü°øÇÐÀÌ Å©°Ô ¹ßÀüÇÔ¿¡ µû¶ó °úÇÐÀÚµéÀº ¹é½Å, È£¸£¸ó, Ç÷¾× ¼ººÐ°ú °°Àº ÷´Ü »ý¹°Á¦Á¦¸¦ ¼³°èÇÏ°í °³¹ßÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, ÀÌ´Â ÇコÄÉ¾î ¹× ±âŸ »ê¾÷ ºÐ¾ß¿¡¼­ Áß¿äÇÑ ÀÀ¿ëÀ» ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¼ºÀå ±âȸ´Â ¿©ÀüÈ÷ Å©Áö¸¸, ³ôÀº R&D ºñ¿ë°ú ¾ö°ÝÇÑ ±ÔÁ¦´Â ¿©ÀüÈ÷ °úÁ¦·Î ³²¾Æ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¸¸¼ºÁúȯ ¹× »ýȰ½À°üº´ÀÇ À¯º´·ü Áõ°¡, ´Ù¾çÇÑ °Ç°­¹®Á¦¿¡ Ãë¾àÇÑ ³ë·ÉÀα¸ÀÇ ±ÞÁõ, ¿ì¼öÇÑ ÇコÄɾî Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ã·´Ü ´Ü¹éÁú ¿£Áö´Ï¾î¸µ, ÀçÁ¶ÇÕ DNA ±â¼ú, Áٱ⼼Æ÷ ¿¬±¸¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ±â¾÷ÀÇ ¸·´ëÇÑ ÅõÀÚ·Î ÀÎÇØ »õ·Î¿î »ý¹°ÇÐÀû ¾à¹° ¹× Ä¡·á¹ý °³¹ßÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ±×·¯³ª ÀÓ»ó½ÃÇè¿¡¼­ ½ÂÀο¡ À̸£´Â ÀǾàǰ °³¹ß °ü·Ã ºñ¿ëÀÌ ¸Å¿ì ³ô°í, ¼¶¼¼ÇÑ Á¦Á¶ °øÁ¤°ú ¾ö°ÝÇÑ ±ÔÁ¦ °¨µ¶À¸·Î ÀÎÇØ ½ÃÀåÀÇ ±Þ¼ÓÇÑ È®ÀåÀº ¿©ÀüÈ÷ ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ ¸ÂÃãÇü ÀÇ·á¿Í Á¶Á÷ ¹× Àå±â 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¹ßÀüÀÇ »õ·Î¿î ±æÀ» Á¦½ÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸ ±â°ü°ú ¾÷°è ±â¾÷ÀÇ ÆÄÆ®³Ê½ÊÀº À¯¸ÁÇÑ ½Å¾à Èĺ¸¹°ÁúÀÇ »ó¿ëÈ­¸¦ °¡¼ÓÈ­ÇÏ°í »ý»ê ºñ¿ëÀ» ³·Ãß´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.

ÁÖ¿ä ±â¾÷¿¡´Â Novartis AG, Johnson &Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck &Co, Inc., GSK Plc, Regeneron Pharmaceuticals µîÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Á¦Ç° À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦5Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, ¿ëµµº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦6Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, À¯Çüº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦7Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦8Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, ȯÀÚ Àα¸ µ¿Åº°, 2020-2032³â, (10¾ï ´Þ·¯)

Á¦9Àå ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¹ÙÀÌ¿À¸Þµð½Å ½ÃÀå, Áö¿ªº°, 2020-2032³â, °¡Ä¡(10¾ï ´Þ·¯)

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×

Á¦12Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Biopharmaceutical and Biomedicine Market is estimated to be valued at USD 640.26 Bn in 2025 and is expected to reach USD 1,425.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 640.26 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 12.10% 2032 Value Projection: USD 1,425.17 Bn
Figure. Biopharmaceutical And Biomedicine Market Share (%), By Region 2025
Biopharmaceutical and Biomedicine Market - IMG1

The global biopharmaceutical and biomedicine market has witnessed tremendous growth over the past few decades. Rising investment in research and development activities by both public and private sectors has led to path breaking innovations in the field of biologics, genetic engineering and novel drug development. Advancements in areas such as cell and gene therapy, regenerative medicine, monoclonal antibodies and personalized medicine holds promising prospects for the treatment of chronic and life-threatening diseases. Rapidly aging population and growing incidence of cancer, diabetes and neurological disorders globally has spurred demand for more effective therapeutic options. Moreover, substantial progress in synthetic biology and genetic engineering is allowing scientists to design and develop advanced biologics like vaccines, hormones and blood components, with significant applications in healthcare and other industrial verticals. While growth opportunities remain vast, high R&D costs and stringent regulatory framework continue posing challenges.

Market Dynamics:

The key factors driving the growth of global biopharmaceutical and biomedicine market include rising prevalence of chronic and lifestyle diseases, rapid increase in geriatric population susceptible to various health issues, growing demand for superior healthcare products and services. Moreover, heavy investments by both public and private players in advanced protein engineering, recombinant DNA technology and stem cell research have enabled development of novel biologic drugs and therapies. However, extremely high costs associated with drug development from clinical trial to approval, coupled with delicate manufacturing processes and stringent regulatory oversight continue to restrain faster market expansion. At the same time, growing focus on personalized medicine and 3D bioprinting of tissues and organ present new avenues for market progress. In addition, partnerships between research institutes and industry players are helping accelerate commercialization of promising drug candidates and lower production costs.

Key Features of the Study:

This report provides in-depth analysis of the global biopharmaceutical and biomedicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global biopharmaceutical and biomedicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, Hoffmann-La Roche AG, AbbVie Inc., Bristol-Myers Squibb, Qiagen N.V., Affimed N.V., Celgene Corporation, Amgen Inc., Merck & Co., Inc., GSK Plc, and Regeneron Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceutical and biomedicine market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2020-2032, (USD Bn)

5. Global Biopharmaceutical and Biomedicine Market, By Application, 2020-2032, (USD Bn)

6. Global Biopharmaceutical and Biomedicine Market, By Type, 2020-2032, (USD Bn)

7. Global Biopharmaceutical and Biomedicine Market, By Route of Administration, 2020-2032, (USD Bn)

8. Global Biopharmaceutical and Biomedicine Market, By Patient Demographics, 2020-2032, (USD Bn)

9. Global Biopharmaceutical and Biomedicine Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â